ArticleJournal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine2020
Obstructive Lung Disease and Obstructive Sleep Apnea (OLDOSA) cohort study: 10-year assessment.
Article in Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Implementation of long-term noninvasive positive airway pressure therapy in patients with COPD: a systematic review and meta-analysis of acceptance and adherence.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Positive airway pressure therapy and all-cause and cardiovascular mortality in people with obstructive sleep apnoea: a systematic review and meta-analysis of randomised controlled trials and confounder-adjusted, non-randomised controlled studies.The Lancet. Respiratory medicine · 2025Pooled it
- Management of Patients with Asthma, COPD, and OSA in Outpatient Unit: ACOSOU-Global Perspectives and Challenges.Pulmonary therapy · 2026Review
- The Natural History of Obstructive Sleep Apnea: A Scoping Review.Healthcare (Basel, Switzerland) · 2026Review
- PRISm and the risk for all-cause mortality in relation to sleep disordered breathing: a community-based study.ERJ open research · 2025Article
- Genetic overlap and immunological pathways in asthma-obstructive sleep apnea coexistence.Sleep & breathing = Schlaf & Atmung · 2025Article
- Interrelationship Between Obstructive Sleep Apnea Syndrome and Small Airway Disease: A Comprehensive Review.Biomedicines · 2025Review
- FFMI: A Pivotal Indicator Bridging Pulmonary, Sleep, and Systemic Factors in COPD-OSA Overlap Patients.International journal of chronic obstructive pulmonary disease · 2025Article
- The overlap of chronic obstructive pulmonary disease and obstructive sleep apnea in hospitalizations for acute exacerbation of chronic obstructive pulmonary disease.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2024Article
- Assessment of Obstructive Sleep Apnea Among Patients With Chronic Obstructive Pulmonary Disease in Primary Care.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024Article
- The effects of disease severity and comorbidity on oxidative stress biomarkers in obstructive sleep apnea.Sleep & breathing = Schlaf & Atmung · 2024Article
- Survival and Risk Factors Associated with Mortality in Patients with Sleep Apnoea in Colombia: A Retrospective Cohort Study.Nature and science of sleep · 2024Article
- Revisiting Asthma Obstructive Sleep Apnea Overlap: Current Knowledge and Future Needs.Journal of clinical medicine · 2023Review
- Drug Development from Natural Products Based on the Pathogenic Mechanism of Asthma.International journal of molecular sciences · 2023Review
- The role of ferroptosis in chronic intermittent hypoxia-induced lung injury.BMC pulmonary medicine · 2022Article
- The Overlap Syndrome of Obstructive Sleep Apnea and Chronic Obstructive Pulmonary Disease: A Systematic Review.Biomedicines · 2022Review
- Personalized Medicine and Obstructive Sleep Apnea.Journal of personalized medicine · 2022Review
- Clinical Evaluation and Management of Overlap Syndrome (OS) and Obesity Hypoventilation Syndrome (OHS).Clocks & sleep · 2022Article
- The effect and relative importance of sleep disorders for all-cause mortality in middle-aged and older asthmatics.BMC geriatrics · 2022Article
- Impact of Positive Airway Pressure Therapy Adherence on Outcomes in Patients with Obstructive Sleep Apnea and Chronic Obstructive Pulmonary Disease.American journal of respiratory and critical care medicine · 2022Observational
Corrections and comments
- Commented on byAuthor response.2020
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
objectivesAsthma, chronic obstructive pulmonary disease (COPD), and obstructive sleep apnea (OSA) are very prevalent disorders. Their coexistence in the same individual has an unclear effect on natural history and long-term outcomes.
methodsThe OLDOSA (Obstructive Lung Disease and Obstructive Sleep Apnea) cohort enrolled 4,980 veterans with an acute hospitalization and in whom asthma, COPD, OSA, overlapping conditions, or none of these disorders at baseline had been diagnosed. Pulmonary function, polysomnography, positive airway pressure (PAP) recommendations and adherence, and vital status were collected and analyzed. Various proportional hazards models were built for patients with OSA to test the effect of PAP therapy on survival.
resultsTen-year all-cause cumulative mortality rate was 52.8%; median time to death was 2.7 years. In nonoverlapping asthma, OSA and COPD, mortality rates were 54.2%, 60.4%, and 63.0%, respectively. The overlap syndromes had the following mortality: COPD-OSA 53.2%, asthma-COPD 62.1%, asthma-OSA 63.5%, and triple overlap asthma-COPD-OSA 67.8%. In patients with OSA not on PAP therapy, after adjustment for age, comorbidities, and lung function, risk of death was 1.34 (1.05-1.71) times higher than those undergoing treatment. Similarly, in patients with OSA nonadherent to PAP therapy the adjusted risk of death was 1.78 (1.13-2.82) times higher versus those using it at least 70% of nights and more than 4 hours nightly.
conclusionsIn this large longitudinal cohort of hospitalized veterans with high comorbid burden, asthma, COPD, OSA and their overlap syndromes had very high long-term mortality. In patients with OSA, PAP initiation and superior therapeutic adherence were associated with significantly better survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.